Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00
Provider: New Constructs, LLC
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc and AiCuris announce publication in New England journal of medicine of Phase 2 clinical trial results of investigational antiviral agent Letermovir in bone marrow transplant patients


Thursday, 8 May 2014 09:00am EDT 

Merck & Co Inc:Publishes results from a Phase 2 clinical trial evaluating safety and efficacy of letermovir, an investigational, oral antiviral agent with AiCuris.For prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant.Results published in latest issue of New England Journal of Medicine(NEJM) show that letermovir in CMV-seropositive allogeneic human blood precursor cell recipients (bone marrow transplant patients) met study's two primary efficacy endpoints.Merck plans to conduct a Phase 3 trial of letermovir, also known as AIC246 or MK-8228, starting in the first half of 2014. 

Company Quote

59.48
0.57 +0.97%
20 Aug 2014